Skip to main content

Table 2 Clinical outcomes of patients with HBV-related acute-on-chronic liver failure on tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment

From: Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B

Outcome, n (%) TAF 25 mg TDF 300 mg ETV 0.5 mg P value
(n = 10) (n = 10) (n = 20)
Mortality or transplantation
 Within 28 days 1 (10) 3 (30) 2 (10) 0.504
 Within 3 months 2 (20) 4 (40) 3 (15) 0.320
 Within 48 weeks 2 (20) 4 (40) 3 (15) 0.320
Liver-related complications (first 3 months)
 Ascites 7 (70) 7 (70) 13 (65) 0.945
 Spontaneous bacterial peritonitis 6 (60) 6 (60) 11 (55) 0.950
 Infection during treatment 3 (30) 4 (40) 7 (35) 0.896
 Gastrointestinal hemorrhage 0 (0) 1 (10) 1 (5) 0.591
 Hepatorenal syndrome 1 (10) 2 (20) 0 (0) 0.244
 Hepatic encephalopathy 0 (0) 2 (20) 1 (5) 0.299